

References

Y-5063

1. Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. *JAMA Oncol.* Jul 13 2017; 3(7): e170580. PMID 28494052
2. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *N Engl J Med.* Oct 15 2015; 373(16): 1541-52. PMID 26465987
3. Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Blood.* Jun 25 2015; 125(26): 4017-23. PMID 25999455
4. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. *J Clin Oncol.* Feb 10 2011; 29(5): 551-65. PMID 21220611
5. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. *J Clin Oncol.* May 10 2010; 28(14): 2339-47. PMID 20385996
6. Bajwa R, Schechter T, Soni S, et al. Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies. *Bone Marrow Transplant.* May 2013; 48(5): 661-5. PMID 23128573
7. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *J Clin Oncol.* Apr 20 2006; 24(12): 1917-23. PMID 16622268
8. von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. *J Clin Oncol.* Dec 20 2016; 34(36): 4381-4389. PMID 27998223
9. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* May 19 2016; 127(20): 2375-90. PMID 26980727
10. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood.* Jan 01 2006; 107(1): 265-76. PMID 16150940
11. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. *Blood.* Jan 01 2015; 125(1): 22-32. PMID 25499448

12. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood*. Oct 19 2017; 130(16): 1800-1808. PMID 28774879
13. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol*. Sep 20 2010; 28(27): 4184-90. PMID 20660832
14. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. *Blood*. May 31 2012; 119(22): 5118-25. PMID 22438256
15. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol*. Nov 01 2014; 32(31): 3490-6. PMID 25267740
16. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant*. Jan 2016; 51(1): 51-7. PMID 26367239
17. Rigacci L, Puccini B, Doderio A, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. *Ann Hematol*. Jun 2012; 91(6): 931-9. PMID 22245922
18. Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. *Biol Blood Marrow Transplant*. Jan 2010; 16(1): 35-45. PMID 20053330
19. Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. *Bone Marrow Transplant*. Feb 2017; 52(2): 216-221. PMID 27643872
20. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. Jun 01 1997; 89(11): 3909-18. PMID 9166827
21. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. *Cancer*. Aug 15 2008; 113(4): 791-8. PMID 18615506
22. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin*. Nov 12 2016; 66(6): 443-459. PMID 27618563

23. Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. *Oncotarget*. Dec 22 2017; 8(68): 112516-112529. PMID 29348844
24. Federal Register / Vol. 85, No. 104 / Friday, May 29, 2020 / Proposed Rules; KTEX19; Page 175. Federal Register / Vol. 85, No. 104 / Friday, May 29, 2020 / Proposed Rules. Available at <https://www.govinfo.gov/content/pkg/FR-2020-05-29/pdf/2020-10122.pdf> Accessed Sep 10, 2023.
25. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. *Blood*. Mar 15 1997; 89(6): 2067-78. PMID 9058729
26. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. *J Clin Invest*. Oct 2012; 122(10): 3416-23. PMID 23023712
27. Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. *Blood*. Jan 01 2015; 125(1): 48-55. PMID 25499451
28. Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. *J Clin Oncol*. Apr 20 2019; 37(12): 984-991. PMID 30811293
29. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. *J Clin Oncol*. Apr 10 2016; 34(11): 1256-69. PMID 26755518
30. Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. *Blood*. Mar 24 2016; 127(12): 1559-63. PMID 26764355
31. Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. *Br J Haematol*. Nov 2018; 183(4): 578-587. PMID 30175400
32. Epperla N, Hamadani M, Cashen AF, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. *Hematol Oncol*. Dec 2017; 35(4): 528-535. PMID 28066928
33. Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. *Bone Marrow Transplant*. May 2018; 53(5): 617-624. PMID 29335632
34. Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. *Am J Hematol*. Sep 2015; 90(9): 790-5. PMID 26096944

35. Randall C, Fedoriw Y. Pathology and diagnosis of follicular lymphoma and related entities. *Pathology*. Jan 2020; 52(1): 30-39. PMID 31791624
36. Cancer Stat Facts: NHL Follicular Lymphoma.
<https://seer.cancer.gov/statfacts/html/follicular.html>. Accessed Sep 10, 2023.
37. Flinn IW, Miller CB, Ardeschna KM, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. *J Clin Oncol*. Apr 10 2019; 37(11): 912-922. PMID 30742566
38. Gopal AK, Kahl BS, de Vos S, et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*. Mar 13 2014; 370(11): 1008-18. PMID 24450858
39. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. *J Clin Oncol*. Dec 10 2017; 35(35): 3898-3905. PMID 28976790
40. National Comprehensive Cancer Network (NCCN). B-Cell Lymphomas. Version 5.2023. July 7, 2023;
<https://www.nccn.org/professionals/physician/gls/pdf/b-cell.pdf>. Accessed Sep 11, 2023.
41. National Comprehensive Cancer Network (NCCN). Acute Lymphoblastic Leukemia. Version 2.2023. July 28, 2023;
https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf. Accessed Sep 10, 2023.
42. Lee DW, Santomaso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. Apr 2019; 25(4): 625-638. PMID 30592986
43. National Cancer Institute. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017 Nov 27;
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed Sep 10, 2023.
44. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med*. Feb 01 2018; 378(5): 439-448. PMID 29385370
45. Laetsch TW, Maude SL, Rives S, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. *J Clin Oncol*. Mar 20 2023; 41(9): 1664-1669. PMID 36399695
46. Laetsch TW, Myers GD, Baruchel A, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. *Lancet Oncol*. Dec 2019; 20(12): 1710-1718. PMID 31606419

47. Bishop MR, Dickinson M, Purtil D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *N Engl J Med*. Feb 17 2022; 386(7): 629-639. PMID 34904798
48. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med*. Sep 02 2015; 7(303): 303ra139. PMID 26333935
49. Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. *Crit Care Med*. Feb 2017; 45(2): e124-e131. PMID 27632680
50. Leahy AB, Newman H, Li Y, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. *Lancet Haematol*. Oct 2021; 8(10): e711-e722. PMID 34560014
51. Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. *J Immunother Cancer*. Aug 2021; 9(8). PMID 34353848
52. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. Jul 10 2014; 124(2): 188-95. PMID 24876563
53. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol*. Feb 10 2007; 25(5): 579-86. PMID 17242396
54. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol*. Sep 20 2014; 32(27): 3059-68. PMID 25113753
55. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. Jan 03 2019; 380(1): 45-56. PMID 30501490
56. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. Oct 2021; 22(10): 1403-1415. PMID 34516954
57. Maziarz RT, Waller EK, Jaeger U, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv*. Feb 25 2020; 4(4): 629-637. PMID 32074277
58. Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*. Feb 2022; 28(2): 325-332. PMID 34921238

59. Prescribing Label: Kymriah (tisagenlecleucel) suspension for intravenous infusion. Initial Approval 2017 Available at <https://www.novartis.us/sites/www.novartis.us/files/kymriah.pdf> Accessed Sep 10, 2023.
60. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol.* Jan 2019; 20(1): 31-42. PMID 30518502
61. Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. *Blood.* May 11 2023; 141(19): 2307-2315. PMID 36821768
62. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med.* Feb 17 2022; 386(7): 640-654. PMID 34891224
63. Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. *N Engl J Med.* Jul 13 2023; 389(2): 148-157. PMID 37272527
64. Elsayy M, Chavez JC, Avivi I, et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. *Blood.* Nov 24 2022; 140(21): 2248-2260. PMID 35839452
65. Prescribing Label: Yescarta (axicabtagene ciloleucel) suspension for intravenous infusion. 2017; Available at <https://www.gilead.com/-/media/files/pdfs/medicines/oncology/yescarta/yescarta-pi.pdf> Accessed Sep 10, 2023.
66. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med.* Dec 28 2017; 377(26): 2531-2544. PMID 29226797
67. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol.* Jan 2022; 23(1): 91-103. PMID 34895487
68. Palomba ML, Ghione P, Patel AR, et al. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. *Expert Rev Anticancer Ther.* Feb 2023; 23(2): 199-206. PMID 36723678
69. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med.* Apr 02 2020; 382(14): 1331-1342. PMID 32242358
70. Prescribing Label: Tecartus (brexucabtagene autoleucel) suspension for intravenous infusion. Initial Approval 2020 Available at <https://www.gilead.com/->

/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf Accessed on Sep 10, 2023.

71. Wang Y, Jain P, Locke FL, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol*. May 10 2023; 41(14): 2594-2606. PMID 36753699
72. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. *Lancet*. Aug 07 2021; 398(10299): 491-502. PMID 34097852
73. Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. *J Hematol Oncol*. Dec 10 2022; 15(1): 170. PMID 36494725
74. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet*. Sep 19 2020; 396(10254): 839-852. PMID 32888407
75. Patrick DL, Powers A, Jun MP, et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. *Blood Adv*. Apr 27 2021; 5(8): 2245-2255. PMID 33904895
76. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*. Jun 18 2022; 399(10343): 2294-2308. PMID 35717989
77. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. *Lancet Oncol*. Aug 2022; 23(8): 1066-1077. PMID 35839786
78. Prescribing label: Breyanzi (lisocabtagene maraleucel) suspension for intravenous infusion. Initial Approval 2021 Available at https://packageinserts.bms.com/pi/pi_breyanzi.pdf Accessed Sep 10, 2023.
79. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukemia in people aged up to 25 years. Technology appraisal guidance Published: 21 December 2018. Available at <https://www.nice.org.uk/guidance/ta554>. Accessed on Sep 10, 2023.
80. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies Technology appraisal guidance

[TA567] Published: 13 March 2019. Available at

<https://www.nice.org.uk/guidance/ta567>. Accessed on Sep 10, 2023.

81. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies.

Technology appraisal guidance [TA559] Published: 23 January 2019. Available at <https://www.nice.org.uk/guidance/ta559> Accessed on Sep 10, 2023.

82. Autologous antiCD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma. Technology appraisal guidance Published: 24 February 2021. Available at <https://www.nice.org.uk/guidance/ta677> Accessed on Sep 10, 2023.

83. Centers for Medicare & Medicaid Services (CMS). Proposed Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N). 2017 Feb 15; <https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=291>. Accessed Sep 10, 2023.